Evidence map›Paper›PMID 42411267›Full record

ArticleCell transplantation

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.

Xia Shao, Miao Zhang, Huiying Qiu, Jun Yang, Xinxin Xia, Yu Cai, Yin Tong, Chongmei Huang, Baoxia Dong, Kun Zhou and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xia ShaoDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Miao ZhangDepartment of Hematology, The Affiliated Fuyang People's Hospital of Anhui Medical University (Fuyang People's Hospital), Fuyang, China.
Huiying QiuDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Jun YangDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Xinxin XiaDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Yu CaiDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Yin TongDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Chongmei HuangDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Baoxia DongDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Kun ZhouDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.
Liping WanDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.ORCID 0000-0001-6868-0258
Yuhu FengDepartment of Hematology, The Affiliated Fuyang People's Hospital of Anhui Medical University (Fuyang People's Hospital), Fuyang, China.
Xianmin SongDepartment of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai General Hospital, Shanghai, China.ORCID 0000-0003-0637-5324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant relapse remains the chief therapeutic challenge in Ph-negative B cell acute lymphoblastic leukemia (Ph

Indexed as

Antibodies, BispecificPeripheral Blood Stem Cell TransplantationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultBridge TherapyChildFemaleGraft vs Host DiseaseHumansMaleMiddle AgedNeoplasm, ResidualRetrospective StudiesTransplantation, HomologousYoung AdultAntibodies, Bispecificblinatumomaballogeneic peripheral blood stem cell transplantation (allo-PBSCT)B-cell acute lymphoblastic leukemia (B-ALL)philadelphia chromosome-negative (Ph-)short-course blinatumomab

Identifiers

PMID42411267
PMCPMC13342381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.